References

  1. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76-94. PubMed | Google Scholar

  2. Marzocchi G, Castagnetti F, Luatti S et al. Variant Philadelphia translocations: molecular-cytogenetic chararcterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011 Jun 23;117(25):6793-800. PubMed | Google Scholar

  3. Huret JL. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukemia. Hum Genet. 1990 Oct;85(6):565-8. Google Scholar

  4. Hagemeijer A, de Klein A, Gödde-Salz E et al. Translocation of c-abl to “masked” Ph in chronic myeloid leukemia. Cancer Genet Cytogenet. 1985 Oct;18(2):95-104. PubMed | Google Scholar

  5. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984 Apr;63(4):789-99. PubMed | Google Scholar

  6. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8. PubMed | Google Scholar

  7. Hasford J, Baccarani M, Hoffmann V et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOBEUTOS score. Blood. 2011 Jul 21;118(3):686-92. PubMed | Google Scholar

  8. Hughes T, Deininger M, Hochhaus A et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 1;108(1):28-37. PubMed | Google Scholar

  9. Baccarani M, Deininger MW, Rosti G et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872-84. Google Scholar

  10. Mkrtchyan H, Ghazaryan S, Avetisyan G et al. Novel complex t(V;9;22) rearrangements in three cases with chronic myeloid leukemia and a rare translocation in a case with classical Philadelphia chromosome. Oncol Rep. 2008 Jul;20(1):99-104. PubMed | Google Scholar

  11. Eyupoglu D, Bozkurt S, Haznedaroglu I, Buyukasik Y, Guven D. The impact of variant Philadelphia chromosome translocations on the clinical course of chronic myeloid leukemia. Turk J Haematol. 2016 Mar 5;33(1):60-5. PubMed | Google Scholar

  12. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. 2010. Accessed on 09 May 2016.

  13. Bakshi SR, Patel BP, Brahmbhatt MM et al. Complex karyotype with a masked Philadelphia translocation and variant BCR-ABL fusion in CML. Cancer Genet Cytogenet. 2009 Mar;189(2):142-3. PubMed | Google Scholar

  14. Okada M, Satake A, Kaida K et al. Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. Int J Hematol. 2011 Feb;93(2):243-246. PubMed | Google Scholar

  15. Nishii K, Usui E, Sakakura M et al. Additional t(11;17)(q23;q21) in a patient with Philadelphia-positive mixed lineage antigen-expressing leukemia. Cancer Genet Cytogenet. 2001 Apr 1;126(1):8-12. PubMed | Google Scholar

  16. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CMl demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet. 2005 Feb;157(1):53-61. PubMed | Google Scholar

  17. Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valgañón M, Chanalaris A et al. FISH mapping of Philadelphia negative BCR/ABL1 positive CML. Mol Cytogenet. 2008 Jul 18;1:14. PubMed | Google Scholar